Letter: when to withhold anti‐TNF agents prior to abdominal surgery in patients with Crohn’s disease—the jury might still be out. Authors’ reply

Linked ContentThis article is linked to Lin et al and Gates papers. To view these articles, visit https://doi.org/10.1111/apt.15184 and https://doi.org/10.1111/apt.15384.

Saved in:
Bibliographic Details
Published inAlimentary pharmacology & therapeutics Vol. 50; no. 4; pp. 465 - 466
Main Authors Lin, Yang‐Sheng, Lin, Wei‐Chen, Chen, Ming‐Jen, Wang, Yuan‐Hung, Chen, Chiehfeng
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.08.2019
Subjects
Crohn Disease
Gastrointestinal Agents
Humans
Infliximab
Postoperative Complications
Surgery
Tumor Necrosis Factor-alpha
Online AccessGet full text

Cover

More Information
Summary:Linked ContentThis article is linked to Lin et al and Gates papers. To view these articles, visit https://doi.org/10.1111/apt.15184 and https://doi.org/10.1111/apt.15384.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.15398